Letermovir for cytomegalovirus prophylaxis after allogeneic hematopoietic stem cell transplantation in acute leukemia patients: results of the LETreal study. (PubMed, Front Immunol) - Sep 19, 2026 - "The incidence of cs-CMVi between 100 and 200 days after allo-HSCT was comparable between patients with prolonged letermovir prophylaxis and those without letermovir prophylaxis. We confirmed the efficacy of letermovir prophylaxis in different subgroups, but the subgroup who would benefit most from prolonged prophylaxis should be further clarified in the future."
Journal • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Transplantation
|
|
Daoxing Deng; Fengrong Wang; Jinfang Zhao; Jing Liu; Jingzhi Wang; Jun Kong; Lanping Xu; Leqing Cao; Qi Wen; Wei Han; Xiaodong Mo; Xiaohui Zhang; Xiaojun Huang; Yao Chen; Yi Xia; Yifei Cheng; Yu Wang; Yuanyuan Zhang; Yuhong Chen; Yuqian Sun
|